Kalbe Farma Tbk PT (KLBF) - Total Assets
Based on the latest financial reports, Kalbe Farma Tbk PT (KLBF) holds total assets worth Rp33.08 Trillion IDR (≈ $1.94 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kalbe Farma Tbk PT - Total Assets Trend (2000–2025)
This chart illustrates how Kalbe Farma Tbk PT's total assets have evolved over time, based on quarterly financial data. Also see how much is Kalbe Farma Tbk PT worth for the company's overall valuation and market capitalisation.
Kalbe Farma Tbk PT - Asset Composition Analysis
Current Asset Composition (December 2025)
Kalbe Farma Tbk PT's total assets of Rp33.08 Trillion consist of 60.3% current assets and 39.7% non-current assets. Review debt load of Kalbe Farma Tbk PT to assess the company's total debt and financial obligations.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp1.80 Trillion | 14.1% |
| Accounts Receivable | Rp5.90 Trillion | 19.2% |
| Inventory | Rp6.99 Trillion | 22.8% |
| Property, Plant & Equipment | Rp8.74 Trillion | 28.5% |
| Intangible Assets | Rp1.69 Trillion | 5.5% |
| Goodwill | Rp626.80 Billion | 2.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Kalbe Farma Tbk PT's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Kalbe Farma Tbk PT share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kalbe Farma Tbk PT's current assets represent 60.3% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 14.1% of total assets in 2025, up from 7.4% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 6.0% in 2000.
- Asset Diversification: The largest asset category is property, plant & equipment at 28.5% of total assets.
Kalbe Farma Tbk PT Competitors by Total Assets
Key competitors of Kalbe Farma Tbk PT based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
NYSE:AZN
|
USA | $115.70 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$201.13 Billion |
|
Sanofi
MX:SNYN
|
Mexico | MX$129.06 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $32.09 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.80 Billion |
|
Novartis AG ADR
NYSE:NVS
|
USA | $122.03 Billion |
|
Organon & Co
NYSE:OGN
|
USA | $13.18 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
Kalbe Farma Tbk PT - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.15 | 3.78 | 4.34 |
| Quick Ratio | 1.96 | 2.30 | 3.02 |
| Cash Ratio | 0.00 | 0.37 | 0.86 |
| Working Capital | Rp14.33 Trillion | Rp12.92 Trillion | Rp11.10 Trillion |
Kalbe Farma Tbk PT - Advanced Valuation Insights
This section examines the relationship between Kalbe Farma Tbk PT's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.41 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | Rp30.70 Trillion |
| Market Capitalization | $2.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Kalbe Farma Tbk PT's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Kalbe Farma Tbk PT's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kalbe Farma Tbk PT (2000–2025)
The table below shows the annual total assets of Kalbe Farma Tbk PT from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Rp30.70 Trillion ≈ $1.80 Billion |
+4.31% |
| 2024-12-31 | Rp29.43 Trillion ≈ $1.72 Billion |
+8.77% |
| 2023-12-31 | Rp27.06 Trillion ≈ $1.59 Billion |
-0.67% |
| 2022-12-31 | Rp27.24 Trillion ≈ $1.60 Billion |
+6.14% |
| 2021-12-31 | Rp25.67 Trillion ≈ $1.50 Billion |
+13.75% |
| 2020-12-31 | Rp22.56 Trillion ≈ $1.32 Billion |
+11.35% |
| 2019-12-31 | Rp20.26 Trillion ≈ $1.19 Billion |
+11.67% |
| 2018-12-31 | Rp18.15 Trillion ≈ $1.06 Billion |
+9.21% |
| 2017-12-31 | Rp16.62 Trillion ≈ $973.65 Million |
+9.13% |
| 2016-12-31 | Rp15.23 Trillion ≈ $892.18 Million |
+11.17% |
| 2015-12-31 | Rp13.70 Trillion ≈ $802.56 Million |
+10.23% |
| 2014-12-31 | Rp12.43 Trillion ≈ $728.06 Million |
+9.81% |
| 2013-12-31 | Rp11.32 Trillion ≈ $663.02 Million |
+20.14% |
| 2012-12-31 | Rp9.42 Trillion ≈ $551.85 Million |
+13.82% |
| 2011-12-31 | Rp8.27 Trillion ≈ $484.86 Million |
+17.66% |
| 2010-12-31 | Rp7.03 Trillion ≈ $412.08 Million |
+8.49% |
| 2009-12-31 | Rp6.48 Trillion ≈ $379.85 Million |
+13.65% |
| 2008-12-31 | Rp5.70 Trillion ≈ $334.22 Million |
+11.01% |
| 2007-12-31 | Rp5.14 Trillion ≈ $301.08 Million |
+11.11% |
| 2006-12-31 | Rp4.62 Trillion ≈ $270.98 Million |
-0.19% |
| 2005-12-31 | Rp4.63 Trillion ≈ $271.50 Million |
+53.58% |
| 2004-12-31 | Rp3.02 Trillion ≈ $176.78 Million |
+23.22% |
| 2003-12-31 | Rp2.45 Trillion ≈ $143.47 Million |
+21.48% |
| 2002-12-31 | Rp2.02 Trillion ≈ $118.10 Million |
+7.36% |
| 2001-12-31 | Rp1.88 Trillion ≈ $110.00 Million |
+6.80% |
| 2000-12-31 | Rp1.76 Trillion ≈ $103.00 Million |
-- |
About Kalbe Farma Tbk PT
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devi… Read more